𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma : A Phase II multicentric trial

✍ Scribed by Jose Luis Pérez-Gracia; Ramon Colomer; Emilio Esteban; Ramón Barceló; Manuel Benavides; Javier Puertas; Alberto Arcediano; María Victoria Tornamira; Vicente Valentín; Alberto Muñoz; Hernán Cortés-Funes; Javier Hornedo

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
110 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of high dose epirubicin
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
✍ Kathy D. Miller; Nikhil Munshi; David Loesch; Lawrence H. Einhorn; George W. Sle 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis

A Phase I dose escalation trial of conti
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma
✍ Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou

Mitoxantrone, 5-fluorouracil, and high d
Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma : A randomized Phase II trial
✍ John D. Hainsworth; Jacques Jolivet; Robert Birch; Lisa G. Hopkins; F. Anthony G 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

Tenfour patients were treated with NFL: mitoxantrone 12 mg/m 2 IV on Day 1; leuconessee. vorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding

A phase I/II study of sequential, dose-e
A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas
✍ Carsten Bokemeyer; Anke Franzke; Jörg T. Hartmann; Christoph Schöber; Lubomir Ar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

ide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer